Clinical Trials Logo
  1. Home
  2. Hematological Diseases
  3. NCT02240992

MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment

Hematological Diseases Clinical Trial

Official title:
Mesenchymal Stem Cells With or Without G-CSF Mobilized Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplant

Clinical Trial Summary

The purpose of this study is to compare the efficacy of mesenchymal stem cells (MSCs) with or without granulocyte colony-stimulating factor (G-CSF) mobilized peripheral stem cells (PBSC) in treating patients experiencing poor graft function or delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.

Clinical Trial Description

Allogeneic hematopoietic stem cell transplantation(allo-HSCT) is the only cure for many hematologic diseases. However, about 5-27% of patients would suffer from poor graft function (PGF) and more recipients might develop delayed platelet engraftment (DPE) after allo-HSCT. These complications are associated with considerable mortality related to infections or hemorrhagic complications. Treatment of PGF and DPE usually involves hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and thrombopoietin (TPO), or second transplantation, but these methods have dismal effect or even a significant risk of graft-versus-host disease (GVHD).

Mesenchymal stem cells (MSCs) are a form of multipotent adult stem cells that can be isolated from bone marrow (BM), adipose tissue, and cord blood. Clinical applications of human MSCs include improving hematopoietic engraftment, preventing and treating graft-versus-host disease after allo-HSCT and so on. Some studies have shown that MSCs combined with PBSC or cord blood could be useful to improve engraftment after HSCT. Several reports suggested MSCs might be effective in the treatment of PGF.

However, the efficacy of MSCs as single-drug treatment for PGF or DPE is unsatisfactory in our previous study. Therefore, in the present study, G-CSF mobilized PBSC will be used combined with MSCs in the patients with PGF or DPE after allo-HSCT. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02240992
Study type Interventional
Source Nanfang Hospital of Southern Medical University
Contact Ren Lin, MD
Phone +86-020-62787883
Email lansinglinren@hotmail.com
Status Recruiting
Phase Phase 2/Phase 3
Start date September 2014
Completion date December 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02241031 - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Phase 2/Phase 3
Completed NCT02483325 - Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases Phase 2
Recruiting NCT05041933 - Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting
Completed NCT00675038 - Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload N/A
Active, not recruiting NCT03745287 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease Phase 2/Phase 3
Recruiting NCT05505760 - Testing Content Delivery Models for MomConnect N/A
Recruiting NCT01160952 - Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation Phase 2
Recruiting NCT00884364 - Exercise During Chemotherapy for Patients With Hematological Malignancies Phase 3
Completed NCT00892502 - Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? N/A
Active, not recruiting NCT00838643 - Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) N/A
Recruiting NCT05329649 - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) Phase 3
Not yet recruiting NCT06281496 - AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT02661035 - Allo HSCT Using RIC for Hematological Diseases Phase 2
Enrolling by invitation NCT06277479 - Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study
Completed NCT00956358 - Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation N/A
Completed NCT01344681 - Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases Phase 2
Recruiting NCT02083731 - MSC for Treatment of CMV Infection Phase 2
Recruiting NCT02083718 - Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function Phase 2
Recruiting NCT01763086 - Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant Phase 2
Recruiting NCT01763099 - Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Phase 2